Keywords: glaxosmithkline, initiates, ph, iii, clinical, studies, aplaviroc
GlaxoSmithKline initiates Ph III clinical studies with aplaviroc treatment-experienced patients.
Article | 01 August 2005
GlaxoSmithKline has initiated Phase III clinical studies with its entry inhibitor aplaviroc (873140) in HIV treatment-experienced patients. The compound selectively inhibits ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
